Ardelyx, Inc. (ARDX) stock
ARDXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 9/3058% below fair value
$3.18+0.11 (+3.58%)
Close on Nov 17, 2026Market cap $792.42MP/E –Yield –
Ardelyx price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Ardelyx's price to sales ratio was 1.7× on Nov 11, 2026, against 3.5× a year earlier. Over the last 5 years it ranged from 1.7× to 60.9×, with a median of 8.2×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 1.7× | −1.8 |
| 2025 | Dec 31, 2025 | 3.6× | −1.2 |
| 2024 | Dec 31, 2024 | 4.8× | −6.0 |
| 2023 | Dec 29, 2023 | 10.7× | −48.6 |
| 2022 | Dec 30, 2022 | 59.3× | +48.5 |
| 2021 | Dec 31, 2021 | 10.8× | −62.1 |
| 2020 | Dec 31, 2020 | 72.9× | −8.7 |
| 2019 | Apr 30, 2019 | 81.5× | +79.0 |
| 2018 | Dec 31, 2018 | 2.5× | −6.2 |
| 2016 | Apr 29, 2016 | 8.7× | −6.8 |
| 2015 | Dec 31, 2015 | 15.5× | +5.2 |
| 2014 | Dec 31, 2014 | 10.3× | – |
See a number that looks wrong?